½ÃÀ庸°í¼­
»óǰÄÚµå
1553439

´ÜÀϱ¤ÀÚ¹æÃâ ÄÄÇ»ÅÍ´ÜÃþÃÔ¿µ ½ÃÀå ±Ô¸ð, Á¡À¯À², µ¿Ç⠺м® º¸°í¼­ : Á¦Ç°º°, ¿ëµµº°, ÃÖÁ¾ ¿ëµµº°, Áö¿ªº°, ºÎ¹®º° ¿¹Ãø(2024-2030³â)

Single-photon Emission Computed Tomography Market Size, Share & Trends Analysis Report By Product (Stand-alone SPECT Systems, Hybrid SPECT Systems), By Application (Cardiology, Oncology), By End Use, By Region, And Segment Forecasts, 2024 - 2030

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: Grand View Research | ÆäÀÌÁö Á¤º¸: ¿µ¹® 180 Pages | ¹è¼Û¾È³» : 2-10ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

´ÜÀϱ¤ÀÚ¹æÃâ ÄÄÇ»ÅÍ´ÜÃþÃÔ¿µ ½ÃÀå ¼ºÀå°ú µ¿Çâ:

Grand View Research, Inc.ÀÇ ÃֽŠº¸°í¼­¿¡ µû¸£¸é ´ÜÀÏ ±¤ÀÚ ¹æ»ç ´ÜÃþ ÃÔ¿µ ¼¼°è ½ÃÀå ±Ô¸ð´Â 2024³âºÎÅÍ 2030³â±îÁö ¿¬Æò±Õ 2.78%ÀÇ CAGRÀ» ±â·ÏÇÏ¿© 2030³â¿¡´Â 45¾ï 4,000¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

ÀÌ ½ÃÀåÀº ¸î °¡Áö ÁÖ¿ä ¿äÀο¡ ÀÇÇØ ÁÖµµµÇ°í ÀÖ½À´Ï´Ù. ÁÖ¿ä ½ÃÀå ÃËÁø¿äÀÎ Áß Çϳª´Â ¾Ï À¯º´·üÀÇ Áõ°¡ÀÔ´Ï´Ù. ¾Ï, ½ÉÇ÷°üÁúȯ, ½Å°æ Áúȯ°ú °°Àº ¸¸¼º ÁúȯÀÇ À¯º´·ü Áõ°¡´Â ´ÜÀϱ¤ÀÚ¹æÃâ ÄÄÇ»ÅÍ´ÜÃþÃÔ¿µ(SPECT) ½ÃÀåÀÇ Áß¿äÇÑ ÃËÁø¿äÀÎÀÔ´Ï´Ù.

Àα¸ °í·ÉÈ­¿¡ µû¶ó ÀÌ·¯ÇÑ Áúº´ÀÇ ¹ßº´·üÀÌ Áõ°¡ÇÔ¿¡ µû¶ó SPECT ¿µ»ó Áø´Ü°ú °°Àº Á¤È®ÇÑ Áø´Ü µµ±¸¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Ãß¼¼´Â Áúº´ ÁøÇà°ú Ä¡·á È¿°ú¿¡ ´ëÇÑ ÀÚ¼¼ÇÑ ÀλçÀÌÆ®¸¦ Á¦°øÇÒ ¼ö Àִ ÷´Ü ¿µ»ó ±â¼úÀÇ µµÀÔÀ» ¿ä±¸Çϰí ÀÖÀ¸¸ç, ÀÌ´Â ÀÌ Áö¿ªÀÇ SPECT ½ÃÀåÀ» °ßÀÎÇϰí ÀÖ½À´Ï´Ù.

ÀÇ·á ½Ã¼³¿¡ ´ëÇÑ ÀÚ±Ý Áö¿ø°ú ÷´Ü ¿µ»ó ±â¼ú¿¡ ´ëÇÑ Á¢±Ù¼ºÀ» °³¼±ÇÏ´Â ÀÌ´Ï¼ÅÆ¼ºê¸¦ ÅëÇÑ Á¤ºÎÀÇ Áö¿øÀº ½ÃÀå ¼ºÀåÀ» ´õ¿í ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, SPECT¿Í CT(SPECT/CT)¿Í °°Àº ´Ù¸¥ ¿µ»ó Áø´Ü ¾ç½Ä°úÀÇ ÅëÇÕÀº Áø´Ü Á¤È®µµ¸¦ ³ôÀÌ°í ´Ù¾çÇÑ ÀÇ·á ºÐ¾ß¿¡¼­ÀÇ Àû¿ëÀ» È®´ëÇϰí ÀÖ½À´Ï´Ù. Á¦Á¶¾÷ü¿Í ÀÇ·á ¼­ºñ½º Á¦°ø ¾÷ü´Â SPECT ±â¼úÀ» ¹ßÀü½Ã۰í ÀÓ»ó »ç¿ëÀ» È®´ëÇϱâ À§ÇØ Àû±ØÀûÀ¸·Î Çù·ÂÇϰí ÀÖ½À´Ï´Ù.

Cardinal Health, GE Healthcare, Siemens Healthineers µî ½ÃÀåÀÇ ÁÖ¿ä ±â¾÷µéÀº SPECT ½Ã½ºÅÛÀÇ Çõ½Å°ú ÃÖÀûÈ­¸¦ À§ÇÑ ¿¬±¸°³¹ß¿¡ ÅõÀÚÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ÀÌµé ±â¾÷Àº º´¿ø ¹× ¿¬±¸ ±â°ü°ú ÆÄÆ®³Ê½ÊÀ» ¸Î¾î ÀÓ»ó½ÃÇè ¹× SPECT À̹Ì¡¿¡ ÇʼöÀûÀÎ »õ·Î¿î ¹æ»ç¼ºÀǾàǰÀÇ µµÀÔÀ» ÃËÁøÇϰí ÀÖ½À´Ï´Ù. Á¦Á¶¾÷ü¿Í ÀÇ·á±â°üÀÇ Çù·ÂÀº ÀÓ»óÀǰ¡ Ãֽбâ¼úÀ» ½±°Ô ÀÌ¿ëÇÒ ¼ö ÀÖµµ·Ï ÇÏ¿© ȯÀÚÀÇ Ä¡·á °á°ú¸¦ °³¼±ÇÒ ¼ö ÀÖµµ·Ï µ½½À´Ï´Ù.

½ÅÁ¦Ç° Ãâ½Ã¿Í ÷´Ü ±â¼úÀÇ ÅëÇÕÀÌ SPECT ½ÃÀåÀÇ ÁÖ¿ä Æ®·»µåÀÔ´Ï´Ù. ÃÖ±Ù µ¿Çâ¿¡´Â SPECT ½ºÄµÀÇ ¹Î°¨µµ¿Í ƯÀ̼ºÀ» Çâ»ó½ÃŰ´Â °íÇØ»óµµ À̹Ì¡ ½Ã½ºÅÛ°ú »õ·Î¿î ¹æ»ç¼ºÀǾàǰÀÇ °³¹ßÀÌ Æ÷ÇԵ˴ϴÙ. ¿¹¸¦ µé¾î, ÃÖ÷´Ü ½ºÄ³³ÊÀÇ µµÀÔÀº ÀÓ»óÀÇ¿¡°Ô ´õ ³ªÀº Áø´Ü ¹× Ä¡·á °èȹÀ» À§ÇÑ Çâ»óµÈ µµ±¸¸¦ Á¦°øÇÔÀ¸·Î½á QEII °Ç°­ °úÇÐ ¼¾ÅÍÀÇ ÇÙÀÇÇÐ ¼­ºñ½º¿¡ º¯È­¸¦ °¡Á®¿Ã °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ÀÌ´Â Çõ½ÅÀûÀÎ ±â¼ú µµÀÔÀ» ÅëÇØ ¾çÁúÀÇ ÀÇ·á ¼­ºñ½º¸¦ Á¦°øÇϰڴٴ ¼¾ÅÍÀÇ ¾à¼Ó¿¡ ºÎÇÕÇÏ´Â °ÍÀÔ´Ï´Ù. ÀÌ·¯ÇÑ ½ºÄ³³ÊÀÇ ¼³Ä¡´Â ȯÀÚÀÇ ¿¹Èĸ¦ °³¼±Çϱâ À§ÇÑ ÀÇ·á ÀÎÇÁ¶ó¿¡ ´ëÇÑ Áß¿äÇÑ ÅõÀÚ°¡ µÉ °ÍÀ¸·Î ±â´ëµË´Ï´Ù.

¶ÇÇÑ, SPECT/CT¿Í °°Àº ÇÏÀ̺긮µå À̹Ì¡ ½Ã½ºÅÛÀÇ º´¿ø ȯ°æ µµÀÔÀº Á¤È®ÇÑ Áø´Ü ¹× Ä¡·á °èȹ¿¡ ÇʼöÀûÀÎ Á¾ÇÕÀûÀÎ ÇØºÎÇÐÀû ¹× ±â´ÉÀû ¿µ»óÀ» Á¦°øÇÔÀ¸·Î½á ÀÌ ºÐ¾ß¿¡ Çõ¸íÀ» ÀÏÀ¸Ä×½À´Ï´Ù. ¿¹¸¦ µé¾î, 2024³â 5¿ù, ¸Ó½Ã »ø¸®¹ø º´¿ø(Mercy Sullivan Hospital)Àº ÷´Ü SPECT/CT À̹Ì¡ ½Ã½ºÅÛÀ» µµÀÔÇÏ¿© Áø´Ü ´É·ÂÀ» °­È­Çß½À´Ï´Ù. ÷´Ü SPECT¿Í CT ±â¼úÀ» ÅëÇÕÇÑ ÀÌ »õ·Î¿î ½Ã½ºÅÛÀº ´Ù¾çÇÑ Áúȯ¿¡ ´ëÇØ »ó¼¼Çϰí Á¤È®ÇÑ ¿µ»ó Áø´ÜÀ» ÇÒ ¼ö ÀÖµµ·Ï ¼³°èµÇ¾ú½À´Ï´Ù.

ÀÌ ¼³Ä¡´Â º´¿øÀÇ Áß¿äÇÑ ¾÷±×·¹À̵åÀ̸ç, Áúº´À» º¸´Ù È¿°úÀûÀ¸·Î Áø´ÜÇÏ°í ¸ð´ÏÅ͸µÇÏ´Â ´É·ÂÀ» Çâ»ó½Ãų ¼ö ÀÖ½À´Ï´Ù. »õ·Î¿î SPECT/CT ½Ã½ºÅÛÀº ´õ ³ôÀº ÇØ»óµµÀÇ À̹ÌÁö¿Í ´õ Á¤È®ÇÑ Áø´Ü Á¤º¸¸¦ Á¦°øÇÏ¿© ´õ ³ªÀº ȯÀÚ Ä¡·á¸¦ Áö¿øÇÏ´Â °ÍÀ» ¸ñÇ¥·Î ÇÕ´Ï´Ù. ÀÌ·¯ÇÑ ±â¼ú Çõ½ÅÀº Áø´Ü ´É·ÂÀ» Çâ»ó½Ãų »Ó¸¸ ¾Æ´Ï¶ó ÀÇ·á Àü¹®°¡ °£ÀÇ ´ÙÇÐÁ¦Àû Çù·ÂÀ» ÃËÁøÇÏ¿© º¸´Ù È¿°úÀûÀΠȯÀÚ °ü¸® Àü·«À¸·Î À̾îÁú ¼ö ÀÖ½À´Ï´Ù.

ÀÌ ½ÃÀåÀÇ ÁÖ¿ä ¾÷ü·Î´Â GE Healthcare, Siemens Healthineers, Koninklijke Philips N.V., Spectrum Dynamics Medical, Digirad Corporation, MILabs B.V., Mediso Medical Imaging Systems, MiE GmbH µîÀÌ ÀÖ½À´Ï´Ù. ½ºÆåÆ®·³ ´ÙÀ̳»¹Í½º´Â Áö³­ 10¿ù VERITON-CT-400 ½Ã¸®Áî µðÁöÅÐ SPECT/CT ½ºÄ³³Ê¸¦ Ãâ½ÃÇÏ¸ç µðÁöÅÐ ÇÙÀÇÇÐ À̹Ì¡ ºÐ¾ßÀÇ Áøº¸¸¦ ¹ßÇ¥ÇÏ´Â µî ÁÖ¿ä ±â¾÷µéÀÌ Àü ¼¼°è °í°´µéÀ» À§ÇØ Á¦Ç° Ãâ½Ã¿Í °°Àº Àü·«Àû ³ë·ÂÀ» ±â¿ïÀ̰í ÀÖ½À´Ï´Ù. ÀÌ »õ·Î¿î ½ºÄ³³Ê´Â °íü °ËÃâ±â ±â¼úÀ» Ȱ¿ëÇÏ°í ³ÐÀº º¸¾î ±¸¼ºÀ» Ư¡À¸·Î Çϸç, °í¿¡³ÊÁö µ¿À§¿ø¼Ò¸¦ ´õ ³ôÀº Á¤È®µµ¿Í ´É·ÂÀ¸·Î À̹ÌÁöÈ­ÇÒ ¼ö ÀÖ½À´Ï´Ù.

´ÜÀϱ¤ÀÚ¹æÃâ ÄÄÇ»ÅÍ´ÜÃþÃÔ¿µ ½ÃÀå º¸°í¼­ ÇÏÀ̶óÀÌÆ®:

  • Á¦Ç°º°·Î´Â ÇÏÀ̺긮µå SPECT ½Ã½ºÅÛÀÌ 2023³â 67.12%ÀÇ °¡Àå Å« ¸ÅÃâ Á¡À¯À²À» Â÷ÁöÇß½À´Ï´Ù. ÀÌ·¯ÇÑ ÇÏÀ̺긮µå ½Ã½ºÅÛÀº SPECTÀÇ ±â´ÉÀû À̹Ì¡ ±â´É°ú CT ¶Ç´Â MRI°¡ Á¦°øÇÏ´Â ÇØºÎÇÐÀû ¼¼ºÎ »çÇ×À» ÅëÇÕÇÏ¿© Áø´Ü Á¤È®µµ¿Í Ä¡·á °èȹÀ» Çâ»ó½ÃŰ´Â Á¾ÇÕÀûÀÎ ºä¸¦ Á¦°øÇÕ´Ï´Ù. ÇÏÀ̺긮µå SPECT ½Ã½ºÅÛÀº Á¾¾çÇÐ, ¼øÈ¯±âÇÐ, ½Å°æÇÐ µî ´Ù¾çÇÑ ÀÇ·á ºÐ¾ß¿¡ »ç¿ëµÇ¾î ½ÅüÀÇ »ý¸®Àû, ÇØºÎÇÐÀû Ãø¸é¿¡ ´ëÇÑ ÀÚ¼¼ÇÑ ÀλçÀÌÆ®¸¦ Á¦°øÇÕ´Ï´Ù.
  • ¿ëµµº°·Î´Â Á¾¾çÇÐÀÌ 2023³â 49.58%·Î °¡Àå Å« Á¡À¯À²À» Â÷ÁöÇÏ¸ç ½ÃÀåÀ» ÁÖµµÇϰí ÀÖ½À´Ï´Ù. Àü ¼¼°è ¾Ï ¹ßº´·üÀÇ Áõ°¡´Â ÇÙÀÇÇÐ À̹Ì¡ ½ÃÀå, ƯÈ÷ PET ¹× SPECT ±â¼úÀÇ ¼ºÀåÀ» ÁÖµµÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Ã·´Ü ¿µ»ó ±â¼úÀº ¾ÏÀÇ ºÐÀÚÀû Ư¼ºÀ» ½Ã°¢È­ÇÒ ¼ö Àִ Ź¿ùÇÑ ´É·ÂÀ¸·Î ÀÎÇØ ³Î¸® äÅõǾî Áúº´¿¡ ´ëÇÑ ´õ ±íÀº ÀÌÇØ¸¦ °¡Á®´ÙÁÖ°í ÀÖ½À´Ï´Ù.
  • ÃÖÁ¾ ¿ëµµº°·Î´Â º´¿ø ºÐ¾ß°¡ 2023³â 46.9%·Î °¡Àå Å« ½ÃÀå Á¡À¯À²À» Â÷ÁöÇß½À´Ï´Ù. ÀÌ´Â ¾Ï°ú CVD¸¦ Á¶±â¿¡ ¹ß°ßÇÏ°í ½Å¼ÓÇÑ °³ÀÔ°ú Ä¡·á¸¦ °¡´ÉÇÏ°Ô ÇÏ´Â º´¿øÀÇ Ã·´Ü À̹Ì¡ ±â¼ú ´öºÐÀÔ´Ï´Ù. ¶ÇÇÑ, ÀÓ»óÀû ¿ä±¸¸¦ ÃæÁ·½Ã۱â À§ÇÑ º´¿ø°ú Ÿ»ç¿ÍÀÇ Á¦ÈÞ ¹× Çù·Â °ü°èµµ ½ÃÀå ¼ºÀå¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù.
  • ºÏ¹Ì´Â źźÇÑ ÇコÄÉ¾î ºÎ¹®, Çõ½Å¿¡ ´ëÇÑ Çå½Å, ÷´Ü ÀÎÇÁ¶ó, R&D¿¡ ´ëÇÑ °­Á¶, ¾Ï ¹× ¸¸¼ºÁúȯÀÇ ³ôÀº À¯º´·ü, Çõ½ÅÀûÀÎ ±â¼úÀÇ ºü¸¥ µµÀÔ µîÀÇ ¿äÀÎÀ¸·Î ÀÎÇØ ¼¼°è ½ÃÀåÀ» µ¶Á¡Çϰí ÀÖ½À´Ï´Ù.
  • ¾Æ½Ã¾ÆÅÂÆò¾çÀº 2024³âºÎÅÍ 2030³â±îÁö ¿¹Ãø ±â°£ µ¿¾È CAGR 3.51%·Î °¡Àå ºü¸£°Ô ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý°ú ¹üÀ§

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ´ÜÀϱ¤ÀÚ¹æÃâ ÄÄÇ»ÅÍ´ÜÃþÃÔ¿µ(SPECT) ½ÃÀå º¯¼ö, µ¿Çâ, ¹üÀ§

  • ½ÃÀå °èÅë Àü¸Á
    • »óºÎ ½ÃÀå Àü¸Á
    • °ü·Ã/ºÎ¼ö ½ÃÀå Àü¸Á
  • ½ÃÀå ¿ªÇÐ
    • ½ÃÀå °ßÀÎ ¿äÀÎ ºÐ¼®
    • ½ÃÀå ¼ºÀå ¾ïÁ¦¿äÀÎ ºÐ¼®
  • ´ÜÀϱ¤ÀÚ¹æÃâ ÄÄÇ»ÅÍ´ÜÃþÃÔ¿µ(SPECT) ½ÃÀå ºÐ¼® Åø
    • ¾÷°è ºÐ¼® - Porter's Five Forces ºÐ¼®
    • PESTEL ºÐ¼®

Á¦4Àå ´ÜÀϱ¤ÀÚ¹æÃâ ÄÄÇ»ÅÍ´ÜÃþÃÔ¿µ(SPECT) ½ÃÀå : Á¦Ç°º° ÃßÁ¤¡¤µ¿Ç⠺м®

  • ºÎ¹® ´ë½Ãº¸µå
  • ¼¼°èÀÇ ´ÜÀϱ¤ÀÚ¹æÃâ ÄÄÇ»ÅÍ´ÜÃþÃÔ¿µ ½ÃÀå : Á¦Ç° º¯µ¿ ºÐ¼®
  • ¼¼°èÀÇ ´ÜÀϱ¤ÀÚ¹æÃâ ÄÄÇ»ÅÍ´ÜÃþÃÔ¿µ ½ÃÀå ±Ô¸ð¿Í µ¿Ç⠺м®, 2018-2030³â
  • µ¶¸³Çü SPECT ½Ã½ºÅÛ
  • ÇÏÀ̺긮µå SPECT ½Ã½ºÅÛ

Á¦5Àå ´ÜÀϱ¤ÀÚ¹æÃâ ÄÄÇ»ÅÍ´ÜÃþÃÔ¿µ(SPECT) ½ÃÀå : ¿ëµµº° ÃßÁ¤¡¤µ¿Ç⠺м®

  • ºÎ¹® ´ë½Ãº¸µå
  • ¼¼°èÀÇ ´ÜÀϱ¤ÀÚ¹æÃâ ÄÄÇ»ÅÍ´ÜÃþÃÔ¿µ ½ÃÀå : ¿ëµµ º¯µ¿ ºÐ¼®
  • ¼¼°èÀÇ ´ÜÀϱ¤ÀÚ¹æÃâ ÄÄÇ»ÅÍ´ÜÃþÃÔ¿µ ½ÃÀå ±Ô¸ð¿Í µ¿Ç⠺м®, 2018-2030³â
  • 2018³âºÎÅÍ 2030³â±îÁö ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø ¹× µ¿Ç⠺м®
  • ½ÉÀ庴ÇÐ
    • ½ÃÀå ÃßÁ¤°ú ¿¹Ãø 2018-2030³â
  • Á¾¾çÇÐ
    • ½ÃÀå ÃßÁ¤°ú ¿¹Ãø 2018-2030³â
  • ½Å°æÇÐ
    • ½ÃÀå ÃßÁ¤°ú ¿¹Ãø 2018-2030³â
  • ±âŸ ¿ëµµ
    • ½ÃÀå ÃßÁ¤°ú ¿¹Ãø 2018-2030³â

Á¦6Àå ´ÜÀϱ¤ÀÚ¹æÃâ ÄÄÇ»ÅÍ´ÜÃþÃÔ¿µ(SPECT) ½ÃÀå : ÃÖÁ¾ ¿ëµµº° ÃßÁ¤¡¤µ¿Ç⠺м®

  • ºÎ¹® ´ë½Ãº¸µå
  • ¼¼°èÀÇ ´ÜÀϱ¤ÀÚ¹æÃâ ÄÄÇ»ÅÍ´ÜÃþÃÔ¿µ ½ÃÀå : ÃÖÁ¾ ¿ëµµ º¯µ¿ ºÐ¼®
  • ¼¼°èÀÇ ´ÜÀϱ¤ÀÚ¹æÃâ ÄÄÇ»ÅÍ´ÜÃþÃÔ¿µ ½ÃÀå ±Ô¸ð¿Í µ¿Ç⠺м®, 2018-2030³â
  • º´¿ø
  • ¿µ»ó Áø´Ü ¼¾ÅÍ
  • ±âŸ

Á¦7Àå ´ÜÀϱ¤ÀÚ¹æÃâ ÄÄÇ»ÅÍ´ÜÃþÃÔ¿µ(SPECT) ½ÃÀå : Á¦Ç°, ¿ëµµ, ÃÖÁ¾ ¿ëµµº° Áö¿ª ÃßÁ¤¡¤µ¿Ç⠺м®

  • Áö¿ªº° ½ÃÀå Á¡À¯À² ºÐ¼®, 2023³â ¹× 2030³â
  • Áö¿ª ½ÃÀå ´ë½Ãº¸µå
  • ¼¼°è Áö¿ª ½ÃÀå ÇöȲ
  • ½ÃÀå ±Ô¸ð, ¿¹Ãø µ¿Ç⠺м®, 2018-2030³â
  • ºÏ¹Ì
  • À¯·´
  • ¾Æ½Ã¾ÆÅÂÆò¾ç
  • ¶óƾ¾Æ¸Þ¸®Ä«
  • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«

Á¦8Àå °æÀï »óȲ

  • ÁÖ¿ä ½ÃÀå ÁøÃâ ±â¾÷ÀÇ ÃÖ±Ù µ¿Çâ°ú ¿µÇ⠺м®
  • ±â¾÷/°æÀï ºÐ·ù
  • ÁÖ¿ä ±â¾÷ÀÇ ½ÃÀå Á¡À¯À² ºÐ¼®, 2023³â
  • ±â¾÷ Æ÷Áö¼Ç ºÐ¼®
  • ±â¾÷ ºÐ·ù(½ÅÈï ±â¾÷, À̳뺣ÀÌÅÍ, ¸®´õ)
  • ±â¾÷ °³¿ä
    • GE Healthcare
    • Siemens Healthineers
    • Koninklijke Philips NV
    • Spectrum Dynamics Medical
    • Digirad Corporation
    • MILabs BV
    • Mediso Medical Imaging Systems
    • MiE GmbH
ksm 24.09.24

Single-photon Emission Computed Tomography Market Growth & Trends:

The global single-photon emission computed tomography market size is expected to reach USD 4.54 billion by 2030, registering a CAGR of 2.78% from 2024 to 2030, according to a new report by Grand View Research, Inc. The market is driven by several key factors. One of the primary market drivers is the increasing prevalence of cancer. The increasing prevalence of chronic disorders such as cancer, cardiovascular diseases, and neurological conditions is a significant driver of the single-photon emission computed tomography (SPECT) market.

As the population ages, the incidence of these diseases rises, creating a greater demand for accurate diagnostic tools such as SPECT imaging. This trend necessitates the adoption of advanced imaging technologies that can provide detailed insights into disease progression and treatment efficacy, thereby boosting the SPECT market in the region.

Government support through funding for healthcare facilities and initiatives to improve access to advanced imaging technologies is further propelling market growth. In addition, the integration of SPECT with other imaging modalities, such as CT (SPECT/CT), enhances diagnostic accuracy and expands its applications in various medical fields.Manufacturers and healthcare providers are actively collaborating to advance SPECT technology and expand its use in clinical practice.

Major players in the market, such as Cardinal Health, GE Healthcare, and Siemens Healthineers, are investing in research and development to innovate and optimize SPECT systems. These companies are also forming partnerships with hospitals and research institutions to facilitate clinical trials and the introduction of new radiopharmaceuticals, which are essential for SPECT imaging. The collaboration between manufacturers and healthcare facilities ensures that the latest technologies are readily available to clinicians, thereby improving patient outcomes.

The launch of new products and the integration of cutting-edge technologies are key trends in the SPECT market. Recent advancements include the development of high-resolution imaging systems and novel radiopharmaceuticals that enhance the sensitivity and specificity of SPECT scans. For instance, the introduction of a cutting-edge scanner is expected to transform nuclear medicine services at QEII Health Sciences Centre by providing clinicians with enhanced tools for better diagnosis and treatment planning. This aligns with the center's commitment to delivering high-quality healthcare through the adoption of innovative technologies. Such scanner's installation represents a significant investment in healthcare infrastructure, aimed at improving patient outcomes.

Further, the introduction of hybrid imaging systems such as SPECT/CT in hospital settings has revolutionized the field by providing comprehensive anatomical and functional imaging, which is crucial for accurate diagnosis and treatment planning. For instance, in May 2024, Mercy Sullivan Hospital installed a high-tech SPECT/CT imaging system, enhancing its diagnostic capabilities. The new system, which integrates advanced SPECT and CT technologies, was designed to provide detailed and accurate imaging for a variety of medical conditions.

The installation marked a significant upgrade for the hospital, improving its ability to diagnose and monitor diseases more effectively. The new SPECT/CT system aims to support better patient care by offering higher resolution images and more precise diagnostic information.These innovations not only improve diagnostic capabilities but also foster greater interdisciplinary collaboration among healthcare professionals, leading to more effective patient management strategies.

Some of the key players in the market are GE Healthcare, Siemens Healthineers, Koninklijke Philips N.V., Spectrum Dynamics Medical, Digirad Corporation, MILabs B.V., Mediso Medical Imaging Systems, MiE GmbH. Key player are involved in undertaking strategic initiatives such as product launch to cater global clientele. In October 2022, Spectrum Dynamics announced its advancement in digital nuclear medicine imaging with the launch of the VERITON-CT-400 Series Digital SPECT/CT scanners. These new scanners utilize solid-state detector technology and feature a wide-bore configuration, enabling them to image high-energy isotopes with enhanced precision and capability.

Single-photon Emission Computed Tomography Market Report Highlights:

  • Based on product, hybrid SPECT systems accounted for largest revenue share of 67.12% in 2023. These hybrid systems integrate SPECT's functional imaging capabilities with the anatomical detail provided by CT or MRI, offering a comprehensive view that enhances diagnostic accuracy and treatment planning. Hybrid SPECT systems are used in various medical applications, including oncology, cardiology, and neurology, to provide detailed insights into the physiological and anatomical aspects of the body
  • Based on application, oncology dominated the market and accounted for the largest share of 49.58% in 2023. The rising global incidence of cancer is driving the growth of the nuclear imaging market, particularly in PET and SPECT technologies. These advanced modalities have gained widespread adoption due to their unparalleled ability to visualize the molecular characteristics of cancer, providing a deeper understanding of the disease
  • Based on end use, hospitals segment is dominated the end use segments with the largest market share of 46.9% in 2023. This is attributable to advanced imaging technologies in hospitals that enable the early detection of cancer, CVD's, allowing for prompt intervention and treatment. In addition, partnerships & collaborations between hospitals and other companies to meet clinical needs contribute to market growth
  • North America dominated the global market due to the attributed to the well-established healthcare sector, commitment to innovation, advanced infrastructure, a strong emphasis on R&D, the high prevalence of cancer and chronic diseases, and rapid adoption of innovative technologies
  • Asia Pacific region is expected to witness fastest growth with a CAGR of 3.51% over the forecast period from 2024 to 2030, due to presence of manufacturers with innovative devices manufacturing capabilities coupled with accelerated diagnostic research capabilities

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Product
    • 1.2.2. Application
    • 1.2.3. End Use
    • 1.2.4. Regional scope
    • 1.2.5. Estimates and forecasts timeline
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
    • 1.4.5. Details of primary research
      • 1.4.5.1. Data for primary interviews in North America
      • 1.4.5.2. Data for primary interviews in Europe
      • 1.4.5.3. Data for primary interviews in Asia Pacific
      • 1.4.5.4. Data for primary interviews in Latin America
      • 1.4.5.5. Data for Primary interviews in MEA
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Approach 1: Commodity flow approach
    • 1.7.3. Volume price analysis (Model 2)
    • 1.7.4. Approach 2: Volume price analysis
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Product outlook
    • 2.2.2. Application outlook
    • 2.2.3. End use outlook
    • 2.2.4. Regional outlook
  • 2.3. Competitive Insights

Chapter 3. Single-Photon Emission Computed Tomography (SPECT) Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
      • 3.2.1.1. Rising prevalence of cancer
      • 3.2.1.2. Technological advancements
      • 3.2.1.3. Increasing awareness of diagnostic needs
    • 3.2.2. Market restraint analysis
      • 3.2.2.1. lack of skilled professionals
  • 3.3. Single-Photon Emission Computed Tomography (SPECT) Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Supplier power
      • 3.3.1.2. Buyer power
      • 3.3.1.3. Substitution threat
      • 3.3.1.4. Threat of new entrant
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Technological landscape
      • 3.3.2.3. Economic landscape

Chapter 4. Single-Photon Emission Computed Tomography (SPECT) Market: Product Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. Global Single-Photon Emission Computed Tomography (SPECT) Product Market Movement Analysis
  • 4.3. Global Single-Photon Emission Computed Tomography (SPECT) Market Size & Trend Analysis, by Product, 2018 to 2030 (USD Million)
  • 4.4. Stand-alone SPECT Systems
    • 4.4.1. Stand-alone SPECT systems market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.5. Hybrid SPECT Systems
    • 4.5.1. Hybrid SPECT systems market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. Single-Photon Emission Computed Tomography (SPECT) Market: Application Estimates & Trend Analysis

  • 5.1. Segment Dashboard
  • 5.2. Global Single-Photon Emission Computed Tomography (SPECT) Application Market Movement Analysis
  • 5.3. Global Single-Photon Emission Computed Tomography (SPECT) Market Size & Trend Analysis, by Application, 2018 to 2030 (USD Million)
  • 5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 5.5. Cardiology
    • 5.5.1. Cardiology market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.6. Oncology
    • 5.6.1. Oncology market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.7. Neurology
    • 5.7.1. Neurology market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.8. Other Application
    • 5.8.1. Other application market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. Single-Photon Emission Computed Tomography (SPECT) Market: End Use Estimates & Trend Analysis

  • 6.1. Segment Dashboard
  • 6.2. Global Single-Photon Emission Computed Tomography (SPECT) End Use Market Movement Analysis
  • 6.3. Global Single-Photon Emission Computed Tomography (SPECT) Market Size & Trend Analysis, by End Use, 2018 to 2030 (USD Million)
  • 6.4. Hospitals
    • 6.4.1. Hospitals market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.5. Diagnostic Imaging Centers
    • 6.5.1. Diagnostic imaging centers market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.6. Others
    • 6.6.1. Others market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. Single-Photon Emission Computed Tomography (SPECT) Market: Regional Estimates & Trend Analysis By Product, Application, End Use

  • 7.1. Regional Market Share Analysis, 2023 & 2030
  • 7.2. Regional Market Dashboard
  • 7.3. Global Regional Market Snapshot
  • 7.4. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
  • 7.5. North America
    • 7.5.1. U.S.
      • 7.5.1.1. Key country dynamics
      • 7.5.1.2. Competitive scenario
      • 7.5.1.3. Regulatory framework/ reimbursement structure
      • 7.5.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.2. Canada
      • 7.5.2.1. Key country dynamics
      • 7.5.2.2. Competitive scenario
      • 7.5.2.3. Regulatory framework/ reimbursement structure
      • 7.5.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.3. Mexico
      • 7.5.3.1. Key country dynamics
      • 7.5.3.2. Competitive scenario
      • 7.5.3.3. Regulatory framework/ reimbursement structure
      • 7.5.3.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6. Europe
    • 7.6.1. Regulatory framework/ reimbursement structure
    • 7.6.2. UK
      • 7.6.2.1. Key country dynamics
      • 7.6.2.2. Competitive scenario
      • 7.6.2.3. Regulatory framework/ reimbursement structure
      • 7.6.2.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.6.3. Germany
      • 7.6.3.1. Key country dynamics
      • 7.6.3.2. Competitive scenario
      • 7.6.3.3. Regulatory framework/ reimbursement structure
      • 7.6.3.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.6.4. France
      • 7.6.4.1. Key country dynamics
      • 7.6.4.2. Competitive scenario
      • 7.6.4.3. Regulatory framework/ reimbursement structure
      • 7.6.4.4. France market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.6.5. Italy
      • 7.6.5.1. Key country dynamics
      • 7.6.5.2. Competitive scenario
      • 7.6.5.3. Regulatory framework/ reimbursement structure
      • 7.6.5.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.6.6. Spain
      • 7.6.6.1. Key country dynamics
      • 7.6.6.2. Competitive scenario
      • 7.6.6.3. Regulatory framework/ reimbursement structure
      • 7.6.6.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.6.7. Norway
      • 7.6.7.1. Key country dynamics
      • 7.6.7.2. Competitive scenario
      • 7.6.7.3. Regulatory framework/ reimbursement structure
      • 7.6.7.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.6.8. Sweden
      • 7.6.8.1. Key country dynamics
      • 7.6.8.2. Competitive scenario
      • 7.6.8.3. Regulatory framework/ reimbursement structure
      • 7.6.8.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.6.9. Denmark
      • 7.6.9.1. Key country dynamics
      • 7.6.9.2. Competitive scenario
      • 7.6.9.3. Regulatory framework/ reimbursement structure
      • 7.6.9.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.7. Asia Pacific
    • 7.7.1. Regulatory framework/ reimbursement structure
    • 7.7.2. Japan
      • 7.7.2.1. Key country dynamics
      • 7.7.2.2. Competitive scenario
      • 7.7.2.3. Regulatory framework/ reimbursement structure
      • 7.7.2.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.7.3. China
      • 7.7.3.1. Key country dynamics
      • 7.7.3.2. Competitive scenario
      • 7.7.3.3. Regulatory framework/ reimbursement structure
      • 7.7.3.4. China market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.7.4. India
      • 7.7.4.1. Key country dynamics
      • 7.7.4.2. Competitive scenario
      • 7.7.4.3. Regulatory framework/ reimbursement structure
      • 7.7.4.4. India market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.7.5. Australia
      • 7.7.5.1. Key country dynamics
      • 7.7.5.2. Competitive scenario
      • 7.7.5.3. Regulatory framework/ reimbursement structure
      • 7.7.5.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.7.6. South Korea
      • 7.7.6.1. Key country dynamics
      • 7.7.6.2. Competitive scenario
      • 7.7.6.3. Regulatory framework/ reimbursement structure
      • 7.7.6.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.7.7. Thailand
      • 7.7.7.1. Key country dynamics
      • 7.7.7.2. Competitive scenario
      • 7.7.7.3. Regulatory framework/ reimbursement structure
      • 7.7.7.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.8. Latin America
    • 7.8.1. Regulatory framework/ reimbursement structure
    • 7.8.2. Brazil
      • 7.8.2.1. Key country dynamics
      • 7.8.2.2. Competitive scenario
      • 7.8.2.3. Regulatory framework/ reimbursement structure
      • 7.8.2.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.8.3. Argentina
      • 7.8.3.1. Key country dynamics
      • 7.8.3.2. Competitive scenario
      • 7.8.3.3. Regulatory framework/ reimbursement structure
      • 7.8.3.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.9. MEA
    • 7.9.1. Regulatory framework/ reimbursement structure
    • 7.9.2. South Africa
      • 7.9.2.1. Key country dynamics
      • 7.9.2.2. Competitive scenario
      • 7.9.2.3. Regulatory framework/ reimbursement structure
      • 7.9.2.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.9.3. Saudi Arabia
      • 7.9.3.1. Key country dynamics
      • 7.9.3.2. Competitive scenario
      • 7.9.3.3. Regulatory framework/ reimbursement structure
      • 7.9.3.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.9.4. UAE
      • 7.9.4.1. Key country dynamics
      • 7.9.4.2. Competitive scenario
      • 7.9.4.3. Regulatory framework/ reimbursement structure
      • 7.9.4.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.9.5. Kuwait
      • 7.9.5.1. Key country dynamics
      • 7.9.5.2. Competitive scenario
      • 7.9.5.3. Regulatory framework/ reimbursement structure
      • 7.9.5.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 8.2. Company/Competition Categorization
  • 8.3. Key company market share analysis, 2023
  • 8.4. Company Position Analysis
  • 8.5. Company Categorization (Emerging Players, Innovators and Leaders
  • 8.6. Company Profiles
    • 8.6.1. GE Healthcare
      • 8.6.1.1. Company overview
      • 8.6.1.2. Financial performance
      • 8.6.1.3. Application benchmarking
      • 8.6.1.4. Strategic initiatives
    • 8.6.2. Siemens Healthineers
      • 8.6.2.1. Company overview
      • 8.6.2.2. Financial performance
      • 8.6.2.3. Application benchmarking
      • 8.6.2.4. Strategic initiatives
    • 8.6.3. Koninklijke Philips N.V.
      • 8.6.3.1. Company overview
      • 8.6.3.2. Financial performance
      • 8.6.3.3. Application benchmarking
      • 8.6.3.4. Strategic initiatives
    • 8.6.4. Spectrum Dynamics Medical
      • 8.6.4.1. Company overview
      • 8.6.4.2. Financial performance
      • 8.6.4.3. Application benchmarking
      • 8.6.4.4. Strategic initiatives
    • 8.6.5. Digirad Corporation
      • 8.6.5.1. Company overview
      • 8.6.5.2. Financial performance
      • 8.6.5.3. Application benchmarking
      • 8.6.5.4. Strategic initiatives
    • 8.6.6. MILabs B.V.
      • 8.6.6.1. Company overview
      • 8.6.6.2. Financial performance
      • 8.6.6.3. Application benchmarking
      • 8.6.6.4. Strategic initiatives
    • 8.6.7. Mediso Medical Imaging Systems
      • 8.6.7.1. Company overview
      • 8.6.7.2. Financial performance
      • 8.6.7.3. Application benchmarking
      • 8.6.7.4. Strategic initiatives
    • 8.6.8. MiE GmbH
      • 8.6.8.1. Company overview
      • 8.6.8.2. Financial performance
      • 8.6.8.3. Application benchmarking
      • 8.6.8.4. Strategic initiatives
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦